Abstract 603 Table 3

Multivariable Models of the Impact of Disease Activity States Since Cohort Entry on Annual Direct and Indirect Costs

Model A
Annual Direct Costs, coefficient (95%CI) Annual Indirect Costs, coefficient (95%CI)
Active state* 1161 (743, 1579) 3390 (1424, 5356)
Disease duration 333 (249, 417) 1346 (652, 2040)
White race/ethnicity -2049 (-3356, -742) -
Residing outside North America - -13657 (-19202, -8112)
Model B
Remission Off-Treatment** -1296 (-1800, -792) -3353 (-5382, -1323)
Remission On-Treatment -987 (-1550, -424) -3508 (-5761, -1256)
LDA-TC -1037 (-1853, -222) -3229 (-5681, -778)
mLLDAS -1307 (-2194, -420) -3822 (-6309, -1334)
Disease duration 330 (245, 415) 1353 (662, 2044)
White race/ethnicity -1996 (-3319, -674) -
Residing outside North America - -13569 (-19040, -8097)
Difference between disease activity state coefficients (95%CI)
Remission On vs Remission Off-Treatment 309 (-304, 921) -156 (-1680, 1369)
LDA-TC vs Remission Off-Treatment 259 (-660, 1117) 123 (-1812, 2058)
LDA-TC vs Remission On-Treatment -50 (-924, 824) 279 (-1400, 1959)
mLLDAS vs Remission Off-Treatment -11 (-902, 881) -469 (-2259, 1321)
mLLDAS vs Remission On-Treatment -320 (-1255, 616) -313 (-2741, 2115)
mLLDAS vs LDA-TC -270 (-1365, 826) -592 (-3056, 1872)
  • *Reference group for active state in Model A is all other disease activity states

  • ** Reference group for all disease activity states in Model B is active state

  • LDA-TC: Low disease activity – Toronto Cohort; mLLDAS: modified Lupus Low Disease Activity State